Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WebMD to post safety notices

This article was originally published in The Silver Sheet

Executive Summary

Consumers will have expanded access to device safety information thanks to a new partnership between FDA and the popular health information Web site WebMD. Announced Dec. 3, the pact could boost the number of patients seeing agency alerts from 130,000 a month currently to tens of millions. The agreement calls for WebMD to feature at least 50 FDA-written articles on its Web site during the coming year, plus provide a link to the agency's full catalog of consumer updates. Further, FDA information will be published in at least three issues of WebMD's bimonthly magazine, distributed to 85 percent of doctors' offices in the United States. Currently FDA uses a Consumer Health Information page - found at www.fda.gov/consumer/default.htm - to publicize information about safety concerns with specific devices, drugs and foods, but the site gets relatively few visits. During a Dec. 3 press conference, FDA Commissioner Andrew von Eschenbach said the partnership grew out of the agency's ongoing exploration of ways to enhance communications with the public, adding that there are likely to be similar collaborations in the future

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel